CN118843641A - 肾素原受体肽、缀合物及药物组合物 - Google Patents

肾素原受体肽、缀合物及药物组合物 Download PDF

Info

Publication number
CN118843641A
CN118843641A CN202380024740.6A CN202380024740A CN118843641A CN 118843641 A CN118843641 A CN 118843641A CN 202380024740 A CN202380024740 A CN 202380024740A CN 118843641 A CN118843641 A CN 118843641A
Authority
CN
China
Prior art keywords
peptide
mentioned
conjugate
prorenin receptor
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380024740.6A
Other languages
English (en)
Chinese (zh)
Inventor
西山成
北田研人
A·拉赫曼
中神启德
林宏树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagawa University NUC
Original Assignee
Kagawa University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagawa University NUC filed Critical Kagawa University NUC
Publication of CN118843641A publication Critical patent/CN118843641A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
CN202380024740.6A 2022-03-03 2023-02-20 肾素原受体肽、缀合物及药物组合物 Pending CN118843641A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-032709 2022-03-03
JP2022032709 2022-03-03
PCT/JP2023/005966 WO2023167033A1 (ja) 2022-03-03 2023-02-20 プロレニン受容体ペプチド、コンジュゲート、および医薬組成物

Publications (1)

Publication Number Publication Date
CN118843641A true CN118843641A (zh) 2024-10-25

Family

ID=87883498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380024740.6A Pending CN118843641A (zh) 2022-03-03 2023-02-20 肾素原受体肽、缀合物及药物组合物

Country Status (5)

Country Link
US (1) US20250177504A1 (https=)
EP (1) EP4488284A4 (https=)
JP (1) JPWO2023167033A1 (https=)
CN (1) CN118843641A (https=)
WO (1) WO2023167033A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015038041A (ja) * 2011-12-08 2015-02-26 株式会社 免疫生物研究所 高血圧症の予知方法
WO2013124406A1 (en) * 2012-02-22 2013-08-29 Centre National De La Recherche Scientifique New dual biomarker of neurodegeneration and of neuroregeneration
US20150241434A1 (en) * 2012-09-11 2015-08-27 National University Corporation Kagawa University Cancer marker and the use thereof
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
US20160202251A1 (en) 2014-08-01 2016-07-14 Beacle Inc. Virus-like particle for use in immunoassay, blocking agent for use in the immunoassay, and kit comprising the virus-like particle and the blocking agent
WO2018084236A1 (ja) 2016-11-02 2018-05-11 国立大学法人香川大学 プロレニン受容体に対する抗体またはその抗原結合断片、およびその用途
JP6895148B1 (ja) * 2020-03-31 2021-06-30 クラシエホールディングス株式会社 冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定用マーカー、冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定方法、及び冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定するための判定用キット
JP2022032709A (ja) 2020-08-13 2022-02-25 日産化学株式会社 ピリダジノン化合物及び除草剤

Also Published As

Publication number Publication date
EP4488284A1 (en) 2025-01-08
EP4488284A4 (en) 2026-03-11
JPWO2023167033A1 (https=) 2023-09-07
US20250177504A1 (en) 2025-06-05
WO2023167033A1 (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
KR102271498B1 (ko) 종양 치료를 위한 키누레닌 고갈 효소의 투여
JP7080053B2 (ja) 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
JP2016510977A (ja) Ｃｓｆ１治療剤
KR20160130979A (ko) 암 면역요법을 위한 신규한 msln 표적화 dna 백신
CN113286604B (zh) 治疗炎症性疾病的蛋白质
KR102862473B1 (ko) 인간 키누레니나제 효소 및 이의 사용법
CN108697765A (zh) 用于预防或治疗人乳头瘤病毒引起的疾病的含有免疫球蛋白fc融合il-7融合蛋白的药物组合物
TW201825122A (zh) 用精胺酸耗盡劑進行之組合癌症免疫療法
KR20180088458A (ko) 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
CN114746106A (zh) 通过肿瘤中使用il-7融合蛋白增加淋巴细胞数的方法
US8071716B2 (en) Thymus-specific protein
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
CN115490765A (zh) Gpnmb的表位肽及所述表位肽与热休克蛋白的复合物
CN118843641A (zh) 肾素原受体肽、缀合物及药物组合物
JP2025509401A (ja) 頭頸部がん治療のための三重複合薬物投与療法
JP5227028B2 (ja) インターロイキン−２の中和能を有する免疫治療用製剤
WO2012048667A1 (zh) 表皮生长因子受体的外显子缺失变异体
CN116390768A (zh) 具有抗癌活性的免疫调节蛋白-siRNA复合物
US20250154215A1 (en) Pharmaceutical composition for treating colitis or colorectal cancer comprising colon-targeted s100a8/a9-derived specific peptide
CN115490768B (zh) Col1a1的表位肽及所述表位肽与热休克蛋白的复合物
US20180228883A1 (en) Use of the Salmonella SPP Type III Secretion Proteins as a Protective Vaccination
CN112043819B (zh) Lapf及其相关物质在抗感染中的应用
WO2025101551A1 (en) Prostate-specific membrane antigen (psma)-binding peptides and method of use
US20220177548A1 (en) Methods and Compositions for Treating Melanoma
US20230121528A1 (en) Salmonella-based dna vaccines in combination with an antibiotic

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination